NEW BRUNSWICK (dpa-AFX) - Drug major Johnson & Johnson (JNJ) announced Friday that its TECVAYLI (teclistamab) monotherapy has been approved by the European Commission to treat adult patients with ...
JNJ Gets European Approval For TECVAYLI Monotherapy To Treat Relapsed/refractory Multiple Myeloma
Source: Finanznachrichten.de
Read Full Story →